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Since the first demonstration of employing growth factors (GFs) to control cell behaviour in vitro, the
spatiotemporal availability of GFs in vivo has received continuous attention. In particular, the ability to
physically confine the mobility of GFs has been used in various tissue engineering applications e.g.
stents, orthopaedic implants, sutures and contact lenses. The lack of control over the mobility of GFs in
scaffolds jeopardizes their performance in vivo. In this feature article, an overview is given on how to
effectively present GFs on scaffolds. In the first part, non-covalent strategies are described covering
interaction motifs that are generic to direct GF immobilization. In the second part, covalent strategies are
described emphasizing the introduction of reactive groups in existing biomaterials. The feature article
ends with a description of strategies based on the physical entrapment of growth factors.Introduction
Growth factors (GFs) are a powerful class of signalling mole-
cules capable of regulating cellular fate, including adhesion,
migration, proliferation and differentiation, and thus offering
the potential to coordinate events like tissue formation, main-
tenance or regeneration.1 Although GF signalling is initiated
directly upon forming stable complexes with GF receptors,
which reside on the cell surface, complete gene expression is a
much slower process. Therefore, control over the presentation
of GFs in biomaterials is required not only in terms of retained
biological activity upon inclusion of GFs into these materials,
ideally with optimized accessibility to and orientation of the
GFs, but also in terms of extended longevity of the presence of
GFs to obtain efficient cell response.
Endogenously, the mobility of GFs is conned by the extra-
cellular matrix (ECM). Throughout the last few decades,
sophisticated approaches have been developed incorporating
features derived from the ECM.2 Many of these approaches
consist of tethering GFs onto the surface of a (bio)material to
achieve control over their spatial distribution. Other
approaches rely on blending GFs into biopolymers to achieve
temporal control over the GF delivery. Notwithstanding the
progress in the development of employing GFs in scaffolds, the
in vivo performance of such GF-loaded scaffolds in e.g. ortho-
paedic implants, stents, sutures and contact lenses, is still
challenged by the necessary control over the mobility of GFs in
scaffolds.ent of Science and Technology and MESA+
wente, P.O. Box 217, 7500 AE, Enschede,
e.nl; Tel: +31 534892987; Web: www.
hemistry 2014We present an overview of the methodologies presented in
the literature for the presentation of GFs to cells at the cell–
material interfaces. Selected examples are described that
emphasize the different types of strategies irrespective of the
type of GF, (bio)material or application involved. Highlighted
examples range in using non-covalent interactions, covalent
attachment and matrices with the common goal of controlling
the spatiotemporal evolution of the GFs.Non-covalent GF immobilization
The strategy used by the ECM to control the mobility of GFs and
thereby to ensure proper cell functioning is based on non-
covalent interactions between different parts of the ECM and
GFs. When non-covalent interactions are non-directional,
including for example ionic bonds, hydrophobic and polar
interactions, typically GFs are physisorbed. However, non-
covalent interactions exist that are directional, including for
example hydrogen bonds and host–guest interactions.3 The
advantage over non-directional interactions lies in the speci-
city and directionality of the supramolecular interaction and
the tunability of the type and number of interaction motifs. In
addition to a homogeneous and oriented attachment, the
reversibility of immobilization is attractive to tune the extent of
delivery in time. Typically the ECM binds GFs through a
combination of directional and non-directional interactions to
ensure the optimal orientation and temporal availability of
the GFs.
In recent years, researchers have adopted affinity tags for
immobilizing GFs onto surfaces. Many of the interactions
currently used for this purpose have been originally developed
for protein applications.4J. Mater. Chem. B, 2014, 2, 2381–2394 | 2381
Fig. 1 Fabrication of the EGF–SLBs on glass substrates. The EGF was
conjugated to Alexa-647-labeled SAv and the SLB contained 7-nitro-
benz-2-oxa-1,3-diazol-4-yl (NBD). FRAP experiments indicated
binding of EGFs. SLBs were used to study the interaction between
EGFs presented to the specific EGFR on the cell membrane and
cellular signaling. The Attofluor cell chamber was used to maintain the
stability of SLBs while immersed in a NaCl solution.8 Copyright © 2006
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View Article OnlineNitrilotriacetic acid–Ni(II)–hexahistidine interactions
Proteins bearing an engineered hexahistidine (His6)-tag are
employed for the site-specic immobilization on Ni(II)–nitrilo-
triacetic acid (NTA)-functionalized surfaces. NTA is a tetra-
dentate ligand that forms an octahedral complex with Ni(II)
ions, leaving two binding sites available for binding to a His6-
tag. The binding affinity is usually in the range of 106–107 M1.5
This immobilization can be easily reversed by the addition of a
competitive metal binding agent (e.g. imidazole or ethyl-
enediaminetetraacetic acid (EDTA)). Many researchers have
taken advantage of this system for the binding of uorescent
proteins, antibodies, virus proteins, and GFs to surfaces for a
variety of applications.5,6
Iwata and co-workers employed a C-terminal His6-tag on the
recombinant epidermal growth factor (EGF) to immobilize the
EGF onto Ni(II)–NTA surfaces.7 First, the authors described a
method to build arrays of Ni(II)–NTA on gold-coated glass
substrates for the construction of EGF–His6 microarrays.7a,b
Briey, a 1-hexadecanethiol self-assembled monolayer (SAM)
was formed that covered the entire surface. Then, part of the
SAM was photolytically removed in a pre-dened pattern and
these bare gold areas were subsequently functionalized with
11-mercapto-1-undecanoic acid. Further derivatization into
active succinimidyl esters was achieved upon reaction with
N-hydroxysuccinimide (NHS) in the presence of N,N0-dicyclo-
hexylcarbodiimide (DCC).7 Reaction with an appropriate NTA
derivative and incubation with NiSO4 yielded a microarray of
Ni(II)–NTA-terminated spots.7 Aer conrming the presence of
EGF within the array spots, neural stem cells (NSCs) were
cultured on the platforms. While NSCs seeded on chelated EGF–
His spots adhered and proliferated to a substantial number,
NSCs seeded on controls of covalently immobilized EGF spots
were lacking aggregation.7 These results demonstrated that cell
aggregation, proliferation and phenotype maintenance were
mediated more efficiently on chelated EGF–His surfaces as
compared to those with the covalently tethered EGF.7 Most
likely favourable interaction between the EGF and the specic
EGF receptors (EGFRs) on the cell surface takes place on EGF–
His surfaces. In a follow-up study, the authors were able to
relate cell activity with the control over orientation, conforma-
tion and surface stability when immobilizing EGF via His-tag
technology in comparison with the covalently bound EGF via
NHS-chemistry.7c Infrared absorption spectroscopy analysis of
anchored EGF–His suggested that chelated EGFs retain the
same conformation both in solution as well as for physically
adsorbed EGF–His (through ionic bonds). Contrarily, the cova-
lently immobilized EGF exhibited an altered spectrum being
indicative of protein denaturation. In addition, NSCs cultured
on immobilized EGF–His presented a negligible expression of
the bIII neuronal marker and the astrocytic GFAP marker
indicating that on these regions the pluripotent phenotype is
maintained. In contrast, cells outside the pattern expressed
high levels of both bIII and GFAP while the expression of the
stem cell marker nestin was reduced. Taken together, these
results showed a technology to create microarray surfaces to
study the protein-based cell function and that immobilizing2382 | J. Mater. Chem. B, 2014, 2, 2381–2394EGFs employing directional interactions is advantageous to
physisorption and (random) covalent chemistry.Biotin–streptavidin interactions
Similar to the previous strategy, the interaction between biotin
and streptavidin (SAv) has been broadly used to specically bind
proteins to materials.5 This interaction leads to highly stable
and nearly irreversible complexes with a Ka of up to 10
15 M1. An
example of the use of this strategy to immobilize GFs was pre-
sented by Groves et al. in an attempt to understand ligand–
receptor interactions.8 Their approach consisted of the use of a
uid-supported lipid bilayer (SLB) for displaying soluble ligands
to cells.8 In this manner, the authors claimed to obtain a system
combining a solution behaviour (local concentration can be
enriched by reaction–diffusion processes) and a solid behaviour
(with control over the spatial location of the ligands). To prove
the concept, a SLB was doped with a biotin-modied phos-
phatidyl derivative to allow rst binding of SAv and subse-
quently binding of biotinylated EGFs (Fig. 1).8
Successful binding of the EGF to the SLB was demonstrated
by the reduced uidity of the EGF–SLB in comparison to a bare
SLB using uorescence recovery aer photobleaching (FRAP)
experiments.8 Cells from the human breast epithelial cell line
(MCF-10a cells) were used to assess the biological activity of the
platforms. Cells seeded on an EGF–SLB were incubated for 20 h.
Aer this time, cell attachment was visible on EGF–SLBs and
not on bare SLBs.8 Moreover, when a competing antibody for
EGF-receptor tyrosine kinase (EGFR) was added, cell attach-
ment was reduced in the same manner as for platforms in the
absence of EGF. These results suggested that cell attachment is
mediated by binding of EGF to EGFR on SLBs. To verify these
results, cells were treated with Tarceva, a kinase inhibitor of
EGFR, which resulted in a similarly poor cell attachment, con-
rming that activation of EGFR kinase activity is required forWiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
This journal is © The Royal Society of Chemistry 2014
Fig. 2 (a) Two-photon irradiation strategy to simultaneously immo-
bilize barstar–SHH and biotin–CNTF. (b) Loss of the coumarin
protection by two-photon irradiation andmaleimide functionalization.
While the large broken circle corresponds to maleimide–barnase, the
smaller oval corresponds to maleimide–SAv. (c–e) Confocal images
corresponding to different views of the two-regions functionalized
with barstar–SHH–Alexa-488 (green) and biotin–CNTF–Alexa-633
(red). Adapted by permission from Macmillan Publishers Ltd: Nature
Materials. Shoichet et al.11 Copyright © 2011.
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View Article Onlinecell attachment. EGF clustering was observed 100 min aer
plating and further enlarged in time indicating that focal
adhesions are required for cell attachment.8 Additionally,
endocytosis of the complex EGF–EGFR was detected indicating
the progression of cell signalling. When the intrinsic SLB
mobility was reduced by using 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, cell spreading was also reduced at a similar
surface concentration of GF.8 Moreover, fewer EGF clusters were
observed for the lowmobility EGF–SLB.8 These results indicated
that the layer mobility facilitates clustering of EGFs and ulti-
mately cell adhesion and spreading.
In another example given by Park and co-workers the biotin–
SAv strategy was employed for cell transfection purposes.9 In
this case the primary amine groups of EGF were used to couple
NHS–PEG–biotin to yield mono-, di-, and tri-pegylated EGF
species. Then, polyethyleneimine (PEI) and luciferase plasmid
DNA were mixed to form 90 nm positively charged poly-
electrolyte complex particles (PEI–DNA).9 These particles were
coated electrostatically with SAv yielding an effective diameter
from 100 to 200 nm for a SAv–DNA molar ratio of 100. These
SAv–PEI–DNA complexes were used to form supramolecular
complexes with EGF–PEG–biotin conjugates. However, only
when mono-pegylated EGFs were bound to the complexes,
stable nanoparticles were produced, while multi-pegylated
EGFs led to abrupt aggregation at a biotin–SAv molar ratio of
4.9 This DNA delivery platform represented an optimal alter-
native to overcome DNA enzymatic degradation when incubated
with nuclease, suggesting that entrapped plasmid DNA was
effectively protected. Finally, the particles were used to
successfully transfect human epidermoid carcinoma cells
which over-express EGF receptors.9 The transfection efficiency
of PEI–DNA complexes was dependent on surface charge. When
the surface charge became less positive, for example by the
interaction with SAv (EGF le out), adsorptive endocytosis
decreased resulting in a reduced transfection efficiency.9 When
transfection was mediated by the specic interaction between
EGF and EGF receptors, a good transfection efficiency was
observed.9
In another recent example exploiting the interaction
between biotin and SAv, M13 phages were modied to express
biotin-like peptide sequences (HPQ) and/or integrin binding
sequences (RGD) on their coat proteins for the immobilization
of SAv-conjugated basic broblast growth factor (FGF-2) and
nerve growth factor (NGF).10 Some of the advantages of pre-
senting binding points for GFs on phages are that the identical
copies of the phage can be easily produced on a large scale via
bacterial amplication, and the resulting phage can be used to
build nanobrous networks without using additional fabrica-
tion techniques. FGF-2 and NGF could then be bound to the
phage in order to successfully regulate proliferation and
differentiation of hippocampal neural progenitor cells (NPCs)
in a synergistic manner together with RGD.
Shoichet’s group developed an approach for the efficient
spatially controlled immobilization of sonic hedgehog (SHH)
and ciliary neurotrophic factor (CNTF) to promote differentia-
tion of retinal precursors.11 In their case, a 3D thiol-agarose
scaffold was protected with the photolabile coumarin moietyThis journal is © The Royal Society of Chemistry 2014which upon two-photon irradiation could be cleaved yielding
exposed thiol groups only in the illuminated areas. Those thiol
groups could be further modied through the Michael addition
of maleimide terminated SAv or barnase to take advantage of
the orthogonal non-covalent binding pairs SAv–biotin (Kd ¼
1015 M) and barnase–barstar (Kd ¼ 1014 M), respectively. In
this way, once the hydrogel was functionalized with both units,
barstar–SHH and biotin–CNTF could self-sort upon supramo-
lecular interactions with their binding partners (Fig. 2a).11 Aer
analysing the relationship between the scan number and
concentration of immobilized GFs in independent experiments
for each binding pair, the technique was used to simultaneously
immobilize the two proteins following the process in Fig. 2a.
Confocal microscopy was used to sequentially irradiate two
different regions while functionalizing them with either bar-
nase or SAv.11 Since the coumarin protective group has an
intrinsic uorescence, functionalization could be followed by
the loss of uorescence (Fig. 2b). Co-functionalization could be
observed by using two different Alexa uorescent dyes for
labeling the GFs (Fig. 2c–e). Finally, the bioactivity of the non-
cytotoxic scaffolds was conrmed in vitro using retinal
precursor cells (RPCs) since expression of relevant markers was
found.11Peptide amphiphiles
Peptide amphiphiles (PAs) combine the amphiphilic features
from surfactants with peptide sequences possessing biological
functions to self-assemble into 1D nanostructures (Fig. 3) under
physiological conditions.12 Moreover, they represent a highly
robust construction since differences in peptide sequence have
a minimum impact on the self-assembly process. Throughout
the last few decades, Stupp et al. have pioneered the develop-
ment of such supramolecular PA nanostructures for use in
tissue regeneration.13 For example, PA-bers were employed for
direct binding and delivery of transforming growth factor b1
(TGF-b1).14a One PA-ber consists of a PA bearing at the
N-terminus the HSNGLPL epitope (identied by phage display)
with a high binding affinity to TGF b1 (ref. 14b) mixed withJ. Mater. Chem. B, 2014, 2, 2381–2394 | 2383
Fig. 3 Design of PAs with chondrogenic potential. Chemical structure
of (A) TGF-b1-binding PA and (B) filler PA. (C) Illustration of the
resulting self-assembled nanofibers displaying the accessible TGF-b1-
binding sequences. (D) TGF-b1 release profile for nanofibers
composed of only filler PA or filler PA containing a 10% of TGF-b1-
binding PA (TGFBPA).14a Copyright © 2010.
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View Article Onlineanother PA bearing a biologically passive sequence that acts as a
ller peptide to control the distribution and accessibility of the
binding epitopes (Fig. 3). These PA-bers could support the
viability and chondrogenic differentiation of mesenchymal
stem cells (MSCs). First, the authors demonstrated a slower
release of TGF-b1 in the case in which pre-loaded nanobers
containing 10 mol% of TGF-b1-binding PA were used in
comparison to TGF-b1 supplemented to bers assembled from
only ller PA.14b MSCs were not only viable within the PA gel in
vitro but they also showed an increased expression of cartilage
markers in the presence of TGF-b1 for TGF-b1-binding PA bers
compared to bers of ller PA aer 4 weeks of culture.14b The in
vivo potential of the bers was further evaluated in full thick-
ness chondral defects in a rabbit model. The defects were lled
with the PA bers and aer 12 weeks of treatment, macroscopic
differences were observed for defects treated with TGF-b1-
binding PA bers both with and without TGF-b1 compared to
those treated either with TGF-b1 alone or with non-bioactive
ller PA (Fig. 3d).14b For the TGF-b1 loaded as well as unloa-
ded TGF-b1-binding PA bers, the defect was nearly lled by
new tissue similar in color and texture to the surrounding car-
tilage.14b The fact that unloaded TGF-b1-binding PA bers were
able to regenerate the tissue in the defects as effectively as in the
presence of exogenous TGF-b1 was explained by the ability to
bind endogenously presents TGF-b1, e.g. from the bleeding
marrow or surrounding synovial uid. In another example
using a supramolecular material, PA was used as a scaffold to
bind platelet-derived growth factor BB (PDGF-BB), vascular
endothelial growth factor A (VEGF-A), FGF-2 and angiopoietin-1
(Ang-1).15a A prolonged PDGF-BB delivery was found for up to 14
days when delivered together with PA gel with potential appli-
cations in the preservation of myocardial function.15a Moreover,
FGF-2 was also bound to the PA matrix by mixing the GF
with a PA aqueous solution resulting in the in situ formation of a
3D scaffold inducing angiogenesis in vivo and in vitro.15b Lee
et al. were able to decorate the periphery of the PA bers with2384 | J. Mater. Chem. B, 2014, 2, 2381–2394biotin to allow the specic interaction with SAv and biotinylated
insulin-like growth factor 1 (IGF 1).16 The presence of IGF-1
bound to these PA-bers was 5-fold higher than to PA-ber
lacking biotin.18 These PA-bers were used to treat rat
neonatal cardiac myocytes and Akt phosphorylation was
analyzed as it represents a downstream target of IGF-1
signaling. Fibers loaded with biotinylated IGF-1 induced Akt
phosphorylation 5-fold aer prolonged delivery for 14 days
compared to either PA-bers alone or untethered IGF-1.16 When
the IGF-1 loaded bers were delivered in vivo to the myocardium
of rats, an enhanced GF retention was observed up to 28 days in
comparison to the soluble one, which was rapidly eliminated.16
Additionally, aer 14 days Akt activation was detected in tissues
with tethered IGF-1 but not with the controls without tethered
IGF-1.16 Tethered IGF-1 further reduced implanted car-
diomyocyte apoptosis while increasing cell growth was
observed.16
Immobilized peptides
Recently, our group reported the covalent co-immobilization of
a cysteine-terminated TGF-b1-binding peptide sequence
(CLPLGNSH) together with a peptide sequence with a binding
affinity for collagen type-II (CLRGRYW) therefore conferring
cartilage regeneration and targeting properties respectively to
the biosurfaces.17 In brief, a uorogenic monolayer was used
to directly visualize the step-wise orthogonal covalent
co-immobilization of both peptides. Subsequently, TGF-b1 and
collagen type-II could be self-sorted from a mixture in a region-
selective manner resulting in a bi-functional protein platform.
In addition, surfaces with immobilized TGF-b1-binding peptide
pre-loaded with the GF showed excellent bioactivity in combi-
nation with human articular chondrocytes (HACs) and stimu-
lated expression of early chondrogenic markers.17
The use of systems promoting specic biological response
without the need for exogenous GFs or transplanted cells was
demonstrated by Kiessling and co-workers. The fabricated
surfaces presented covalently attached peptides with binding
affinity to TGF-b1 receptors.18 These platforms were reported
not to compete with the GF but rather to sensitize bound mouse
mammary gland cells (NMuMG) to subpicomolar concentra-
tions of endogenous TGF-b (Kd  5 pM).18
Heparin-based systems
In the late 1990s, an increasing interest in the interactions
between proteins and glycosaminoglycans (GAGs) arose. In
particular, heparin and heparan sulfate interactions with
proteins with relevant biological functions have been exhaus-
tively studied to date and several reviews have appeared on the
topic.19 Heparin and heparan sulfate, both present in the ECM,
are sulfated, linear, unbranched polysaccharides structurally
composed of disaccharide repeated units.19b They contain
dimers of uronic acid and 1,4-linked glucosamine. While the
major occurring disaccharide sequences in heparin contain
three sulfonate groups, heparan sulfate contains only an
average of less than 1 per disaccharide.19a O-Sulfated saccha-
rides have been found both in heparin and heparan sulfate forThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinethe specic interaction with various members of the FGF
family.20 Heparin exists primarily as a helical structure. The key
of the specicity of the interaction of heparin with proteins is
suggested to rely on a dened orientation and distribution
pattern of the charges of both the sulfonate and carboxyl groups
at the exterior of the helix.19b Several consensus sequences
including basic and hydropathic (neutral and hydrophobic)
amino acid residues with turns in the secondary structure
(which bring basic amino acid residues into proximity)
have been frequently reported for the interaction with a multi-
tude of GFs.19a
As an example, Linhardt and co-workers presented a
collection of studies regarding the interaction of acidic FGF-1,
basic FGF-2 and TGF-b1 with heparin.19a Aer structural
analysis of the three GFs, a common motif was found:
TXXBXXTBXXXTBB (where T denes a proline turn, B a basic
amino acid residue such as arginine or lysine (or occasionally
a hydrogen bonding glutamine) and X a hydropathic residue).
This interaction resulted in a complex with a dissociation
constant in the 109 M order for FGF-2 complexed with
heparin.21 Moreover, competitive binding studies in the pres-
ence of different concentrations of NaCl served to determine
that only 30% of the binding free energy is caused by pure
electrostatic interactions while the rest of the contributions
rely mostly on hydrophobic interactions and hydrogen
bonding through the hydroxyl groups present in heparin.21 As
can be seen above, one of the most well studied heparin-
binding proteins is FGF with a high affinity for heparan
sulfate proteoglycans on the cell surface. FGF binds specically
to cell surface receptors called broblast growth factor recep-
tors (FGFRs) and, interestingly, via multiple interacting points.
Therefore, for the success of the interaction a simultaneous
ternary complex formation is required.22 Within this context,
heparan sulfate mediates FGFR dimerization, necessary to
initiate signal transduction, by binding several FGFs next to
each other. Depending on the FGF and FGFR pairs, the
complex will be 1 : 1 : 1 interacting with another 1 : 1 : 1 and
thus resulting in a 2 : 2 : 2 complex for the pair FGF-2 and
FGFR-1 or 2 : 2 : 1 for FGF-1 and FGFR-2 with heparin as
reported by Schlessinger et al.23 and Pellegrini et al.24 respec-
tively (Fig. 4).Fig. 4 Structures of FGF (green)–FGFR (yellow)–heparin (balls)
complexes for FGF-2 : FGFR1 : heparin (left) and FGF-
1 : FGFR2 : heparin (right). Balls (heparin) represent S (yellow), O (red)
and N (blue) atoms.19b Copyright © 2002 Wiley-VCH Verlag GmbH,
Weinheim.
This journal is © The Royal Society of Chemistry 2014Examples describing the interaction of heparin with iso-
forms of the vascular endothelial growth factor (VEGF), TGF-b1,
PDGF and EGF have been presented by Capila and Linhardt as
well.19b These invaluable efforts in exploring and characterizing
in great detail the interactions between several growth factors
and heparin gave origin to a multitude of applications in the
tissue engineering eld.2d,4 Some studies used approaches to
incorporate heparin to a broad range of existent biocompatible
materials in order to improve their GF retention, presentation
and delivery properties. In one example heparin was modied
with methacrylate groups in order to be co-polymerized with
dimethacrylated PEG yielding a hydrogel for the localized
delivery of biologically active FGF-2 for up to 5 weeks. The
complexed FGF-2 was able to promote adhesion, proliferation
and osteogenic differentiation of human mesenchymal stem
cells (hMSCs).25 Bone morphogenetic protein 2 (BMP-2) and
RGD were also presented to hMSCs by this type of hydrogel
resulting in the production of increased levels of osteogenic
markers.26 In another example, hyaluronic acid, gelatin and
heparin were modied with thiol groups and co-cross-linked
with poly(ethylene glycol) diacrylate (PEGDA). These hydrogels
containing only 0.3% of heparin in their composition showed
sustained release of either VEGF or FGF-2 and improved in vitro
neovascularization properties, when compared to hydrogels
without co-cross-linked heparin.27
Titanium surfaces were also functionalized with heparin for
the immobilization of BMP-2 (ref. 28) and VEGF.29 In a recent
example, the activity of heparin-bound VEGF was compared to
that of VEGF tethered covalently to the same type of surface.29b
VEGF was covalently immobilized on Ti-foils coated with hya-
luronic acid–catechol or non-covalently on heparin–catechol.
The Ti-surfaces were used to evaluate the cell response using
endothelial cells (ECs) and osteoblasts. Although similar
surface densities of immobilized GFs were achieved following
both the covalent and non-covalent strategies, the EC response
of the covalently immobilized VEGF was signicantly reduced
when compared to the heparin-bound VEGF.29b In addition, the
latter case led to enhanced mineralization in osteoblast/EC
co-cultures. Moreover, a reduced bacterial infection was
observed in the studies which could be related to the highly
hydrophilic and negatively charged nature of the heparin-
bound Ti surfaces.29b
A range of biomaterials has been covalently cross-linked with
heparins. For example, alginate30 and poly(lactic-co-glycolic
acid) (PLGA)31 are covalently cross-linked with FGF-2 binding
heparin and these materials showed improved in vivo and
in vitro angiogenesis properties when compared to the materials
without heparin. A dendrimer, modied with EGF-binding
heparin, was cross-linked with a collagen gel and successfully
used for inducing the proliferation of human cornea epithelial
cells (HCECs).32 The surface of electrospun bers of poly-
(3-caprolactone) (PCL)/gelatin was covalently modied with
heparin for the binding of PDGF-BB. The bers showed pro-
longed proliferation and smooth muscle cells (SMCs) could
inltrate extensively into the heparin-modied scaffold.33 Poly-
meric micelles of a block copolymer of Tetronic®–PCL–heparin
were prepared by an emulsion and solvent evaporation methodJ. Mater. Chem. B, 2014, 2, 2381–2394 | 2385
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View Article Onlineas an injectable vehicle for long-term delivery of FGF-2 showing
an excellent performance of GF delivery properties.34
An elegant example based on the use of natural matrices
functionalized with heparin was presented by Hubbell’s group
for the controlled delivery of FGF-2 (ref. 35) or b-NGF for nerve
regeneration technology making use of heparin–GF interac-
tions.36 Although b-NGF has only a weak interaction with
heparin,37 the authors postulated that a basic domain present
in b-NGF or other neutrophins such as brain-derived neuro-
trophic factor (BDNF) and neurotriphin-3 (NT-3) could actually
interact with heparin while slowing down the diffusion-based
protein release from a brin matrix. In order to demonstrate
it, brin was decorated with heparin-binding peptides cova-
lently cross-linked to the matrix by the enzymatic activity of
factor XIIIa. Those peptides could subsequently sequester
heparin within the brin matrix. Aer loading the matrix with
b-NGF, its release was studied and compared with a case with
both heparin-binding peptides and heparin being absent.
Without the heparin-binding and heparin components present
in the matrix, the majority of the GF was released within a day,
whereas in the presence of the components, only 50% of the
initial amount of b-NGF was released within a day while 30%
of the initial GF remained stagnant in the matrix aer 15 days.
In addition, a neuronal cell culture model was used to assess
the performance of b-NGF, BDNF, or NT-3 presented via the
heparin-based delivery system resulting in a signicant
enhancement of neurite extension only when heparin-binding
peptides, heparin and GFs were present in comparison to
unmodied brin with b-NGF in the cell culture medium.Fig. 5 Schematic representation of the two redox states of the elec-
tro-responsive GF presentation system. (a) When reduced, PEDOT
becomes neutral while weakening the electrostatic interaction with
heparin which gains then an increased freedom of movement for the
interaction of the heparin-immobilized GF with specific cell receptors.
(b) Contrarily, when oxidized, PEDOT becomes positively charged with
a high affinity for the anionic sulfonate groups of heparin resulting in a
tight structure that hampers the interaction of heparin-bound GFswith
cells. The two states have a clear impact on NSC differentiation. (c)
While interaction with FGF-2 prevents cell differentiation while cells
remain proliferative, (d) a restricted contact with the GF leads to
astrocytic differentiation.38Copyright © 2011Wiley-VCH Verlag GmbH
& Co. KGaA, Weinheim.
2386 | J. Mater. Chem. B, 2014, 2, 2381–2394Another biomimetic anchoring method has been recently
presented for the immobilization of FGF-2 and FGF-8 that
enables a switchable GF bioavailability.38 Here conducting
poly(3,4-ethylenedioxythiophene) (PEDOT) lms were formed
on poly(ethylene terephthalate) (PET) substrates by the oxida-
tive electropolymerization of EDOT, resulting in a net positively
charged polymer. This property was used by Teixeira and
co-workers to form a stable electrostatic complex between the
negatively charged heparin and the positively charged polymer
backbone. The electrochemical responsiveness of the system
was described (Fig. 5). When an electrochemical reduction
process was applied to the system, PEDOT became nearly
neutral, decreasing the ionic binding of heparin to PEDOT, and
when the system was electrochemically oxidized, fully oxidized
PEDOT restored the tight original complex with heparin.38 FGF-
2 could be bound to the negatively charged heparin and upon
applying the PEDOT reductive potential the heparin complex-
ation to the PEDOT lm was disrupted, thereby releasing
FGF-2.38 The authors found signicant stabilization of FGF-2
against enzymatic degradation when compared to soluble
FGF-2, which represents a clear advantage to a daily soluble
dose required in cultures of NCSs.38 In addition the authors
found that the control over the bioavailability of the GF via an
electrochemical stimulus resulted either in undifferentiated
(Fig. 5c) or differentiated (Fig. 5d) NSC cells.
Stupp and co-workers have been exploring the potential of
heparins by decorating the periphery of their PAs with heparins
as pro-angiogenic matrices.39 Aer mixing two aqueous solu-
tions: i.e. one solution containing a PA with a positively charged
peptide sequence (i.e. LRKKLGKA), which is able to bind to
heparin chains (Ka ¼ 107 M1)39a and another solution of
heparin with or without FGF-2 and VEGF, PA–heparin bers
were formed. These PA–heparin bers were reported to bind
FGF-2 and delay its release in comparison to PA in the absence
of heparin. The FGF-2 loaded PA-bers resulted in enhanced
vascularization of a rat cornea in comparison with samples
using PA without heparin or using a PA-ber made of a
scrambled version of the heparin-binding sequence
(i.e. LLGARKKK).39b
HBPAs were also used by the same groups to deliver angio-
genic GFs to extrahepatic islet isogras in diabetic mice while
increasing vascular density in the transplant site. In such a way
improved islet engrament and insulin production was ach-
ieved while reducing the time required to achieve normoglyce-
mia.39c,d Finally, in a more recent example, these authors
combined the use of HBPAs with hyaluronic acid to create a
membrane at their interface.39e This membrane has three
regions: an amorphous layer, a region with PA bers parallel to
the contact interface and a zone with bers aligned perpen-
dicular to the interface.40 These membranes, which can form
in situ, were successfully used to deliver VEGF and FGF-2 in vitro
and promote angiogenesis in vivo.
Recently, Tekinay, Guler and co-workers designed PA-bers
that contain carboxylic acid, hydroxyl and sulfonate groups to
mimic the binding function of heparin.41 A binding constant of
Ka ¼ 106 M1 was found for the VEGF binding to the PA-bers
containing all three charged groups which compares favorablyThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineto the VEGF binding to heparin. SO3
–PA nanobers did not
reveal any VEGF binding but the PA bers with SO3
, COOH and
OH groups exhibited slow VEGF release rates within the narrow
VEGF therapeutic region.41 Culturing human umbilical vein
(hUV)ECs on such multi-charged PA-bers led to the formation
of capillary-like structures without the presence of any exoge-
nous GF. In vivo neo-vascularization of rat corneas was
successfully achieved with GF amounts several times lower than
the ones used in the literature when in combination with
HMPA, providing new opportunities for angiogenesis and
general tissue regeneration. The usability of the system was
lately extended to binding other GFs such as hepatocyte growth
factor (HGF), BMP-2 and NGF with different affinities.42
As described above, the interaction between heparin and GFs
can be used to synthesize heparin-mimicking materials in
which heparin is eventually absent.43 In particular, the example
presented by Maynard’s group shows a method to create micro-
and nanoarrays of FGF-2 and VEGF by using electron beam
(e-beam) lithography (Fig. 6).43b First, the authors designed a
novel synthetic polymer which mimicked heparin to overcome
the limitations of costumed heparin synthesis.43b Poly(sodium
4-styrenesulfonate)-co-poly(ethylene glycol methacrylate)
(PSS-co-PEGMA) was synthesized by reversible addition frag-
mentation chain transfer (RAFT) polymerization yielding SO3

groups, which can be used to mimic heparin.43b These SO3

groups are more stable towards hydrolysis than the SO3
 groups
present in the natural polysaccharides. Moreover, the PEG units
rendered the material biocompatible. Aer polymerization,
n-butylamine was used to reduce the dithioester groups found
at the end of the polymer to create thiol groups for stably
coating gold substrates. Subsequently, SPR experiments
revealed that both VEGF and FGF-2 can bind to PSS-co-PEGMA
in a specic and dose-dependent manner.43b Moreover, theFig. 6 Strategy to create GF nanopatterns on a heparin mimicking
polymer. (a) Films of PSS-co-PEGMA are deposited on Si substrates
and e-beam treated yielding (b) a size tunable microarray or nanoarray
of a heparin mimicking polymer. The platform can then be used for
binding of (c) VEGF or (d) FGF-2. Reprinted with permission.43b
Copyright © 2008 American Chemical Society.
This journal is © The Royal Society of Chemistry 2014GF-PSS-co-PEGMA complex was stable at physiological salt
concentrations.43b Using e-beam lithography allowed the crea-
tion of microarrays on polymer lms that were spin-coated onto
silicon substrates. The e-beam was used to regioselectively
cross-link the PEG block of the polymer to the substrate. Aer
washing with water andmethanol the non-cross-linked polymer
was removed rendering polymer patterns surrounded by back-
ground areas. Within these patterns VEGF or FGF-2 could be
specically immobilized through interactions with the SO3

groups (Fig. 6).
This technology has been recently implemented by these
authors for the co-immobilization of FGF-2 by electrostatic
interaction with the sulfonate groups while ketone-
functionalized RGD was bound covalently through the forma-
tion of an oxime bond with 8-armed aminooxy-terminated PEG
that was co-cross-linked to the substrates together with PSS-co-
PEGMA. The platforms contributed synergistically in the
spreading of hUVECs in comparison to controls.44
Another recent example using heparin–GF interactions was
presented by Lahann and co-workers.45 The authors presented
the synthesis of a novel polymer coating (poly[4-formyl-p-xyly-
lene-co-4-ethynyl-p-xylylene-co-p-xylylene]) bearing two orthog-
onal functional groups i.e. aldehydes and alkynes. Aldehyde-
functionalized heparin was attached to the aldehyde func-
tional group in the polymer through the hydrazide–aldehyde
reaction using a bis-hydrazide crosslinker. Azide-functionalized
cyclic RGD (cRGD) was attached to the alkyne functional groups
in the polymer using the click reaction. FGF-2 was subsequently
immobilized on the heparin-presenting surfaces while the RGD
could lead to better cell adhesion properties.
In a study presented by Segura et al. heparin was immobi-
lized covalently to a SAM on gold.46 Their strategy consisted of
using the heparin-binding domain of VEGF to orient the
molecule and a secondary functional group in the SAM to
mediate covalent bonding, yielding VEGFs that is simulta-
neously covalently as well as non-covalently bound to the
surface.46 This bind-and-lock approach aimed to homogenize
GF orientation prior to the covalent reaction which stabilizes
the GF layers. First, mixed SAMs were formed on gold substrates
consisting of (1-mercapto-11-undecyl)tetra(ethylene glycol)
(EG-OH) and (1-mercapto-11-undexyl)hepta(ethylene glycol)
amine (EG-NH2). Second, an oxidized heparin and a heparin
that was modied with the photoreactive group p-azidobenzoyl
(heparin–ABH), were attached via their aldehyde groups to the
amine groups in the SAM to form a Schiff base, which aer a
reduction step yielded an irreversible bond.46 VEGFs could be
specically immobilized yielding a GF density of around 200 pg
cm2 on either heparin surface.46 VEGF was released up to 80%
for 2 days in PBS, while 40% was released throughout the rst 3
days resulting in a plateau at 100 pg cm2 for both heparin
surfaces. However, irradiation of heparin–ABH yielded cova-
lently bound VEGF resulting in a reduced release.46 Upon
contact between the platforms and porcine aortic (PA)EC over-
expressing KDR (PAEC/KDR), a similar VEGFR-2 phosphoryla-
tion was found for cells in contact with both electrostatically
and covalently immobilized VEGFs.46 Nevertheless, when
hUVECs (endogenously presenting VEGFR-2) were used instead,J. Mater. Chem. B, 2014, 2, 2381–2394 | 2387
Fig. 7 Non-covalently assembled hydrogels for the delivery of GFs.
Hydrogels can be formed either by mixing low molecular weight
(LMWH) PEG or PEG–[heparin mimic] such as a four-armed PEG
modified with sulfated peptides with either GF alone or together with
four-armed PEG decorated with PEG–HBP in order to obtain hydro-
gels with different release and mechanical properties. Reprinted from
Kiick and Kim.49 Copyright © 2007, with permission from Elsevier.
Fig. 8 EGF immobilization strategies. (a) Surface-first and (b) solution-
first approach. Reprinted with permission from Macmillan Publishers
Ltd: Nature Medicine.50 Copyright © 1996.
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View Article Onlinephosphorylation of the receptor was found for both covalent
and non-covalent immobilization approaches again, but in this
case a cut-off was observed aer some time for the phosphor-
ylated receptor for the VEGF delivered in a soluble format,
which was not found for the immobilized one.46 Those results
indicated different phosphorylation kinetics for the immobi-
lized and soluble VEGF. The fact that phosphorylation occurred
for the covalently immobilized VEGF indicated that
phosphorylation can occur without internalization of the ligand
receptor complex. In addition, the different release properties
observed for the electrostatically and covalently bound VEGF
convert these platforms into excellent surfaces for further
studying the VEGF-VEGFR-2 signalling.
Kiick and co-workers employed low molecular weight
heparin-modied star polymers that are assembled into a
physically cross-linked hydrogel network upon addition of
VEGF.47 This hydrogel presented a higher elastic modulus
when cross-linked by the VEGF than upon the addition of a
control protein not interacting with heparin such as BSA. This
conrms that the cross-linking is mediated by the addition of
VEGF.47 30% of the VEGF was released over a 10-day period
when incubated in PBS, however, when incubated in the
presence of VEGF receptor 2 (VEGFR-2), the release was
increased to 80% for the same period of time while the
hydrogel completely disappeared. Maintained VEGF bioac-
tivity was demonstrated since an enhancement in the prolif-
eration of PAEC/KDR was observed for cells cultured in the
presence of the hydrogel. The authors used this novel system
for the presentation of other GFs such as FGF-2 (ref. 47b) or
they used sulfated peptides with binding affinities (106 M1)
for both heparin binding peptides (HBPs)48 and VEGF165
(Fig. 7).492388 | J. Mater. Chem. B, 2014, 2, 2381–2394Covalent GF immobilization
Covalent attachment through amines
A ground-breaking contribution was reported by Kuhl and
Griffith-Cima in which a GF was covalently tethered to a
surface.50 In this example, the authors hypothesized that the
delivery of non-endocytosible and non-diffusable (i.e. tethered
to an insoluble substrate) EGFs can ensure appropriate
numbers of GF receptor complexes during the necessary period
of time for signaling in comparison to soluble factors. To
explore that, star poly(ethylene oxide) (PEO) tethers (40–80 nm
when fully extended) were utilized as tethering units. Two
strategies were used for the immobilization of the GF (Fig. 8): (i)
in the surface-rst approach (Fig. 8a), star PEO was rst
attached to the surface in order to subsequently immobilize
EGFs and (ii) in the solution-rst approach (Fig. 8b), the
conjugation between star PEO and GF was performed in solu-
tion and the complex was then immobilized. Briey, the
surface-rst approach requires rst the attachment of tresyl-
activated PEO star onto an NH2-terminated SAM.50 Aerwards,
native murine EGF was covalently immobilized in a single
conformation through the terminal amine, which is the only
available primary amine on this EGF variant.50 When the
authors omitted the tresyl chloride activation step, EGF could
only be physisorbed onto the background as a control.50 In the
solution-rst method, EGF was conjugated to tresylated PEO
star in the presence of ethylenediamine. Subsequently, the GF
loaded PEO star was reacted through the remaining amine
groups to aldehyde derivatized glass slides.50
For both strategies, DNA synthesis was stimulated in primary
rat hepatocytes in a similar manner as using a comparable
concentration of soluble EGF. Additionally, no biological
response was found by the EGF that was non-specically
adsorbed on the surfaces which the authors related to a
protein conformation unsuited for interactions with EGFR.50
The bioactivity of the tethered EGF was also assessed by
analyzing cell morphological changes and it was observed to
inhibit cell spreading as efficiently as GF delivered in solution in
a similar concentration aer 3 days of cell culture.50 Following a
similar approach, EGF was presented to MSCs while tethered on
100 nm thin lms of PMMA-g-PEO. Such lms exhibited anThis journal is © The Royal Society of Chemistry 2014
Feature Article Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
8 
Ju
ly
 2
01
3.
 D
ow
nl
oa
de
d 
on
 0
7/
04
/2
01
6 
13
:0
4:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineexcellent ability to promote cell spreading and survival for this
cell type in comparison to soluble EGF, even in the presence of
FasL, a potent death factor for humanMSCs,51 while controlling
cell migration.52 In another example, scaffolds of PMMA-g-PEO
were used to tether EGFs to achieve an enhanced osteogenic
colony formation of connective tissue progenitors when
compared to soluble EGF.53
Sako and co-workers used N-(6-maleimidocarpoyloxy)sulfo-
succinimide (sulfo-EMCS) to cross-link the terminal (and only
primary) amine of murine EGF to thiol-modied glass surfaces
while preventing lateral diffusion and internalization of EGF
receptors.54 To this end, NH2-terminated SAMs on glass
were reacted with succinimidyl 6-[30-(2-pyridyldithio)-
propionamido]-hexanoate (LC-SPDP) to further reduce it with
dithiothreitol (DTT) to yield a thiol-terminated SAM.54 EGF
could then be coupled by the reaction with sulfo-EMCS.54 Up to
1 EGF per nm2 was found with uniform density.54 However, the
density could be tuned by changing the concentration of
maleimide-modied EGF dramatically affecting cellular
response. To assess the biological activity of the layers, the
authors cultured epidermoid carcinoma cells on the EGF-
modied SAMs. Aer immunouorescently staining phospho-
tyrosine, the uorescence intensity was found to be consider-
ably higher in cells cultured on the EGF substrates in
comparison to unstimulated cells. This indicates that the EGF
remained active for successful interaction with the EGFR and it
induced dimerization and autophosphorylation of the tyrosine
residues of the receptor.54 Additionally, single-molecule obser-
vation of the dissociation events of Grb2, an adaptor protein
that binds to the phosphorylated EGF receptor, was analyzed for
living cells that were stimulated with the tethered EGF resulting
in a dissociation rate of 0.37 s1 and a dissociation constant of
Kd ¼ 100 nM, demonstrating that the turnover time scale in
living cells falls in the range of seconds.54
In another example, Cavalcanti-Adam and co-workers
recently used NHS-functionalized SAMs on gold for the cova-
lent random immobilization of BMP-2 via the primary amineFig. 9 Strategies to immobilize LIF (a) covalently to POMA, (b) cova-
lently to a flexible PEG spacer arm tethered to POMA and (c) non-
covalently to ECM coating deposited on top of hydrolyzed POMA.
Reprinted with permission from Macmillan Publishers Ltd: Nature
Methods.56a Copyright © 2008.
This journal is © The Royal Society of Chemistry 2014groups of the protein structure leading to surface concentra-
tions of around 70–80 ng cm2.55 Since there are a number of
lysine residues present on the exterior of BMP-2, attachment
may occur simultaneously through several residues, potentially
creating heterogeneity in the population of immobilized
proteins. Nevertheless, BMP-2 remained active upon immobi-
lization while inducing cellular responses on C2C12 myoblasts,
such as phosphorylation of Smad and induction of Smad-
dependent transcription of BMP-2 target genes, while osteo-
genic differentiation was reported.55
Zandstra et al. investigated three approaches for the
presentation of leukemia inhibitory factor (LIF) from poly-
(octadecene-alt-maleic anhydride) (POMA) (Fig. 9).56 Two of the
approaches are based on the covalent attachment of the factor
either directly to POMA (Fig. 9a) or to POMA functionalized with
a exible PEG spacer (POMA–PEG) (Fig. 9b) while the third
approach takes advantage of the non-covalent interaction of the
LIF to POMA pre-coated with ECM components (POMA–matrix)
(Fig. 9c).
To prepare the immobilization platforms, POMA was rst
bound to NH2-functionalized glass and LIF was then immobi-
lized either via direct reaction with the anhydride groups of
freshly annealed polymer or by water-soluble carbodiimide
chemistry (WSC) to the free COOH groups of the PEG spacer in
the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide hydrochloride (EDC) and sulfo-NHS. For the non-covalent
approach, all the anhydride groups were deliberately hydrolyzed
and the polymer was coated either with native collagen type I
and bronectin or gelatin and LIF was then allowed to phys-
isorb.56 125I-radiolabeled LIF was used to quantify the amount
immobilized in each case leading to different amounts. While
saturation was reached for LIF covalently immobilized on
POMA–PEG with a maximum surface density of around
90 ng cm2, incubation with a solution of the same concen-
tration did not saturate POMA with covalently immobilized
LIF.56 This observation is attributed to the fact that POMA–PEG
reduces binding since: (i) it presents a higher hydrophilic
interface for pre-concentrating the protein and (ii) it has a lower
density of binding sites.56 LIF physisorbed to ECM protein
coatings led to a similar density as for LIF that was covalently
immobilized on POMA.56 Nevertheless, comparable surface
densities could be achieved by using solutions of different
concentrations for incubation.56 Additionally, a maximized
retention was found for LIF covalently attached to POMA
whereas accessibility to LIF was maximized for LIF on POMA–
PEG and POMA–matrix in comparison to POMA.56 When mouse
embryonic stem cells (mESCs) were seeded on immobilized LIF
platforms, a dose-dependent activation of STAT3 signaling was
found for covalently immobilized LIF as well as for phosphor-
ylated MAPK in an equal manner as diffusible LIF. Additionally,
immobilized LIF supported mESC pluripotency for at least
2 weeks in the absence of added diffusible LIF.
Using a similar chemical strategy, Radisic and co-workers
presented an approach to decorate collagen scaffolds with
VEGF and angiopoietin-1 (Ang1).57 The authors followed a step
immobilization in which collagen scaffolds were either rst
incubated with EDC, sulfo-NHS and subsequently VEGF wasJ. Mater. Chem. B, 2014, 2, 2381–2394 | 2389
Fig. 10 (a) Synthetic scheme of photoreactive polyallylamine conju-
gated to EGF and (b) substrate preparation and GF patterning strategy
on a polystyrene substrate.
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View Article Onlinecoupled or a bulk immobilization in which the VEGF was pre-
mixed with EDC/sulfo-NHS in order to incubate the scaf-
folds.57 Moreover, different reaction media were used to
perform the reaction (i.e. PBS, water or 2-(N-morpholino)etha-
nesulfonic acid (MES)). The authors found that PBS resulted in
the reaction buffer in which higher GF amounts were immobi-
lized as well as higher proliferation rates of different endothe-
lial cell lines were observed.57 Additionally, step immobilization
was more effective than bulk immobilization in tethering active
forms of the GF. Nevertheless, in any case, immobilized VEGF
or Ang1 resulted in an enhanced cell proliferation and lactate
metabolism when compared to soluble GFs in a similar
concentration. The authors recently corroborated their results
and extended the application of the functionalized scaffold to
an in vitro ventricular free wall defect in rat hearts.58
Similarly, Shin and co-workers recently reported the func-
tionalization of poly(L-lactide-co-3-caprolactone) (PLCL) with the
tethered VEGF59 or the co-immobilization of an RGD-containing
peptide and FGF-2 for their synergistic activity.60 In both cases,
polydopamine was deposited on the surface of PLCL by simply
dipping it in a solution of the compound.61 VEGF could then be
tethered by the reaction of its primary amine or thiol groups via
imine formation or Michael addition reaction. In both cases,
immobilized GF enhanced adhesion and spreading of hUVECs
while improving migration, suggesting that the cells maintain
their biological activity on these platforms.
Another common technique to render material surfaces
reactive for the binding of GFs is the use of plasma polymeri-
zation. For example, Sheardown and co-workers showed a case
in which PDMS was functionalized with amine groups with
plasma polymerization of allylamine.62 EGF could be then
coupled to the reactive primary amine groups on the surface by
the homo-bifunctional NHS-ester of PEG–butanoic acid result-
ing in the immobilization from 40 to 90 ng cm2 of EGF while
remaining active to signicantly promote epithelial cell
coverage when compared to unfunctionalized negative controls.
West and co-authors have frequently reported the use of
acryloyl–PEG–N-hydroxysuccinimide to couple GFs to PEGDA.63
For example, TGF-b1 was tethered following this approach and
it was reported to enhance the matrix production by vascular
smooth muscle cells in comparison to the same amount of
soluble GF.63a This strategy was also used to create gradients of
FGF-2 by photopolymerization, as seen before, to observe that
cells align and migrate in the direction of increasing tethered
FGF-2,63b as well as to tether VEGF that increased endothelial
cell tubulogenesis on the surface of the non-degradable
hydrogel 4-fold compared to the negative control while being
further increased in the presence of a bound RGDS peptide
sequence.63c In a more recent example, the authors showed the
simultaneous immobilization of PDGF-BB and FGF-2 to
promote angiogenesis in vitro with co-cultures of endothelial
cells and mouse pericyte precursor 10T1/2 cells.63d Another
strategy based on WSC was presented for the immobilization of
nerve growth factor (NGF) on gelatin–tricalcium phosphate
membranes by the group of Su.64 The membranes with tethered
GF showed a sustained release of bioactive NGF for up to two
months.2390 | J. Mater. Chem. B, 2014, 2, 2381–2394Covalent attachment through carboxylic acids
The group of Ito presented a strategy to immobilize EGFs with
photoreactive polyallylamine coated on a polystyrene
substrate.65 In short, polyallylamine was functionalized with N-
[4-(azidobenzoyl)oxy]succinimide, yielding a photoreactive
polymer (AzPhPAAm).65 Mouse EGF was then conjugated with
the modied polymer by means of WSC using the carboxylate
groups of the protein structure (Fig. 10) resulting in 1.4 mole-
cules of GF per molecule of AzPhPAAmEGF as determined by
elemental analysis.65 Subsequently, the authors coated a poly-
styrene substrate with AzPhPAAm and upon UV irradiation this
AzPhPAAm was graed onto the polystyrene plate via the reac-
tion of the highly reactive photogenerated nitrenes with
neighboring hydrocarbons.65 Subsequently, AzPhPAAmEGF was
deposited and a photomask was used to selectively crosslink the
EGF-containing materials to the surface into patterns relying on
the same reactive nitrenes.65 Although the strategy is subject to
randomly orienting the EGF to the photoprecursor and prone to
denaturation of the EGF, uorescence immunostaining
demonstrated that a substantial part of the EGF retained its
native conformation.
When Chinese hamster ovary cells overexpressing EGF
receptors were cultured on the patterned substrate, cell adhe-
sion was similar to that without immobilized EGFs. However,
the intensity of immunouorescently labeled phosphorylated
tyrosine was visible only in cells adhered on EGF-immobilized
areas. Patterned EGFs also induced cell proliferation in
contrast to platforms in the absence of GF. This represented one
of the rst examples in which the EGF was immobilized on the
surface of a polymeric matrix with an impact on the study of
EGF signaling transduction and on the manipulation of cells
using articial substrates.
Another GF immobilization strategy requiring UV light or a
pulsed infrared laser to enable immobilization was presented
by the group of Shoichet.66 In this case, VEGF165 was randomlyThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinemodied with 4-(4-N-maleimidophenyl) butyric acid hydrazide
in the presence of EDC and coupled to agarose-thiol via a
Michael addition reaction.66 Fluorescence visualization served
the authors to quantify around 900 ng mL1 of VEGF immobi-
lized within the hydrogel while only 80 ng mL1 was physically
adsorbed. VEGFR2+ bran-derived endothelial (bEnd3) cells were
used to assess the bioactivity of covalently bound GF in
comparison to soluble VEGF in a similar concentration. In both
cases, similar proliferation proles were found indicating that
the covalent VEGF remains active upon immobilization. More
interestingly, gradients of immobilized VEGFs could be created
within the hydrogel to analyze the guiding capacity of the GF to
tubule-like formation mimicking an in vivo VEGF gradient
regulated by interstitial ow. Gradients were created taking
advantage of the photolabile coumarin-protected agarose-
sulde groups. Therefore, controlling the scanning number
and scanning regions of a confocal laser, gradients were
observed upon immobilization of the uorescently labeled
VEGF. Three gradients were created with variations of 2.48, 1.65
and 1.00 ng mL1 per mm and aer 3 days of culture cells were
observed to have penetrated to a depth of more than 200 mm
and to form tubule-like structures for gradients of 1.65 and
1.00 ng mL1 per mm. However, cells cultured on the steeper
gradient (i.e. 2.48 ng mL1) showed no evidence of tubular
formation in the gel. The authors attributed this effect to
saturation of VEGFR2 receptors limiting the cells to sense the
gradient. In fact, the authors argued that as important as the
gradient steepness is the starting concentration of the GF
enhancing or limiting tubule extension. VEGF was also
successfully attached to resorbable PLLA and PCL surfaces
through WSC as presented by Albertsson et al.67Physical entrapment
Traditionally, polymeric matrices and scaffolds have been used
to deliver GFs that were entrapped inside. In this manner,
release is controlled by: (i) diffusion, (ii) swelling, (iii) erosion or
(iv) external stimuli (Fig. 11).4 Either way, control over release
rate, orientation and effective dose is limited. These and new
ndings about the mechanisms that control GF delivery in
organisms and successful efforts to reproduce those from a
synthetic point of view have reduced interest for the delivery of
physically entrapped GFs. However, several interestingFig. 11 Release modes of entrapped drugs in matrices or scaffolds.
This journal is © The Royal Society of Chemistry 2014examples have been found to date. For example Mooney and co-
workers designed a system in which VEGF delivery is based on
the compressive stimulation of an alginate hydrogel.68 Without
mechanical stimulation, the release rate appeared to be
constant (due to other modes presented in Fig. 11) and the
cumulative release was increasing linearly with time. When
mechanical stimuli were applied, the release rate increased ve
times compared to the control and depending on mechanical
input the cumulative release could be up to double compared to
the one for the control without mechanical stimuli. Alginate
hydrogels both loaded and unloaded with VEGFs were
implanted in vivo into the dorsal region of mice.
While no vascularization was observed without VEGFs either
with or without mechanical stimuli, the neighbouring tissue of
the implants showed enhanced vascularization for hydrogels
loaded with VEGFs. Nevertheless, mechanically stimulated
hydrogels showed a signicant increase in vascularization
compared to non-stimulated gels.
The group of Picart is actively involved in the presentation of
diffusive BMP-2 from different material supports coated with
polyelectrolyte matrices.69 Their strategy consists of the layer-by-
layer (LbL) deposition of poly(L-lysine) (PLL) and hyaluronic acid
(HA). Aer covalently cross-linking the lms using EDC chemistry,
these lms were soaked in acidic solutions of BMP-2 to load the
lms with GF (Fig. 12).69b Aer GF loading for 1 h under optimized
conditions, the local concentration of BMP-2 could be increased
up to 500-fold in comparison to the concentration of the loading
solution and it was dependent both on the deposition conditions
and the lm thickness.69b The thickness of the polyelectrolyte
layers was also shown to have an effect on the diffusion of the GF.
While 12 bilayers allowed diffusion, BMP-2 entrapped within 24Fig. 12 (a) Stiffness control and functionalization of polyelectrolyte
LbL-deposited films with BMP-2. The film is formed by alternating the
deposition of PLL and HA (1). EDC concentration and WSC reaction
time can be used to tune the stiffness of the films (2). Incubation with
BMP-2 is used to trap the GF within the film matrix (3). (b) Differences
between the deliveries of soluble or matrix-bound BMP-2. While the
crosstalk between BMP and adhesion receptors is allowed when BMP-
2 is retained by the matrix thus creating a high local concentration of
BMP receptors complexed to the GF in the vicinities of adhesion
receptors, when BMP-2 is presented in solution, receptor diffusion to
interact with soluble factors decreases this cross-talk.69b Copyright ©
2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
J. Mater. Chem. B, 2014, 2, 2381–2394 | 2391
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View Article Onlinebilayer matrices showed a limited capability to diffuse.69b Release
was demonstrated to follow an initial burst for the rst 5 h while
reaching a steady state which prolonged further release for several
days.69b Additionally, the authors suggested a non-covalent inter-
action between BMP-2 and HA gels that could be used to tune the
release properties.69b Finally, they tested this material for the
culture of C2C12 myoblast cells. When C2C12 were seeded on
lms without BMP-2 normal differentiation into myotubes was
observed.69b However, when cells were seeded on loaded lms a
higher activity of ALP was observed as an indication of osteogenic
differentiation while troponin T expression (amarker of myogenic
differentiation) decreased in a dose-dependent manner.69a Inter-
estingly, those lms could be used for three consecutive culture
sequences while BMP-2 remained bioactive, which conrms the
protective role of the polyelectrolyte lms. These initial ndings
spurred the interest of the group to apply these layers, for
example, as a coating of macroporous tricalcium phosphate
(TCP)/hydroxyapatite (HAP) ceramic scaffolds.69c This resulted in
signicant amounts of BMP-2 loaded within the materials with
controlled release properties compared to bare scaffolds and
enhanced osteogenic differentiation remaining bioactive for long
periods of time.69c As mentioned before, the stiffness of the lms
can be modulated by tuning the cross-linking via WSC (Fig. 12).
Using this property, Picart showed that large differences in cell
adhesion, spreading and mobility were found between the
presentation of bound and soluble BMP-2 depending on the
material stiffness.69b For example, no difference in cell spreading
and adhesion was observed for cells cultured on stiff lms both
with bound BMP-2 or BMP-2 delivered in a soluble format. In
contrast, when cells were seeded on so lms a signicant
increase in cell number, area and spreading velocity was observed
in the case in which BMP-2 was loaded in the polyelectrolyte
matrix, whereas no difference was found between BMP-2 deliv-
ered in solution or in the absence of BMP-2. As depicted in Fig. 12,
the authors hypothesized that there must be a cooperation
between BMP receptors and adhesion receptors when BMP
receptors interact with highly localized BMP-2, whichmight affect
cell shape and cytoskeletal dynamics in cases in which cell
adhesion is initially poor (i.e. non-functionalized so lms). In
contrast, when BMP-2 is presented in solution, BMP receptors
diffuse for the complexation with soluble BMP-2 reducing the
cross-talk with adhesion receptors.
BMP-2 was also delivered within a nanostructure made of
high-purity carbon ber web (TCFW) in an approach presented
by Saito et al.70 TCFWs with a diameter of 250 or 1000 nm were
obtained by electrospinning polymer solutions showing good
mechanical properties to function as implants. The scaffolds
could entrap BMP-2 resulting in induction of ectopic new bone
formation in vivo and they could repair large bone defects
orthotopically.
Another interesting way to present GFs is by entrapping
them in cubic inclusion bodies such as polyhedra. Inclusion
bodies are proteinous crystals found for example in Bombyx
mori cytoplasmatic polyhedrosis virus (BmCPV).71 Hiraki et al.
have presented the co-expression of the FGF-2 encoding a
sequence fused to the one for the virion outer capsid protein
VP3 of the BmCPV gene together with the BmCPV polyhedron2392 | J. Mater. Chem. B, 2014, 2, 2381–2394yielding around 10 mm large polyhedra containing FGF-2. The
advantage of these protein crystals is that while they are stable
and insoluble at physiological pH, the release is triggered at
high pH. That was demonstrated by observing FGF-2 released in
cell culture medium containing 5% FBS while no release was
observed in PBS. Mouse chondrogenic cells and broblasts were
cultured in the presence of FGF-2 polyhedra resulting in a
higher proliferation when compared with normal polyhedra,
which was proven to be regulated by the FGF receptors. The
FGF-2 polyhedra were also shown to inhibit chondrogenic
differentiation of ATDC5 as expected resulting in micron sized
bioactive substances.
Recently, Park et al. presented an example of a potential
multiple GF delivery system.72 Their approach consisted of
constructing a matrix of PLGA microspheres coated with
nanospheres of the same material via electrostatic interactions.
Using preloaded nanospheres with dexamethasone (DEX),
negatively charged GFs (i.e. BMP-7, IGF/FGF-2 and TGF-b3) were
complexed with positively charged heparin, which allowed
coating the nanospheres. By embedding hMSCs onto the
nanosphere coated microspheres containing the various GFs,
osteogenic, adipogenic and chondrogenic differentiation were
observed.72 Aer four weeks of culturing hMSCs embedded onto
the nanospheres, the expression levels of GAG, ALP and Oil red
O were evaluated for the determination of their differentia-
tion.72 These results demonstrated the specicity of each coated
GF towards each kind of differentiation compared to a control
in which hMSCs were cultured on bare nanospheres or nano-
spheres loaded with the complementary GFs.72 In addition,
results obtained via reverse transcription polymerase chain
reaction (RT-PCR) andWestern blot of different genes related to
the various differentiation pathways as well as histology and
immunohistochemistry were in agreement.72 Finally, the
transplantation of the scaffolds in vivo into mice showed that
the factors remained in the scaffold matrix for up to 3 weeks,
thereby enabling prolonged stimulation of the differentiation of
the embedded hMSCs.72
Conclusions
To date, a variety and number of methodologies to present GFs
with different materials have shown enormous growth. Most of
the strategies presented in this discussion demonstrated
enhanced stability of the GFs upon immobilization. Enhanced
performances in vitro and in vivo were observed in the case of
immobilized GFs when compared to traditional regenerative
medicine treatments employing soluble GFs. In addition, a
common feature found in all presented strategies is the creation
of high local concentrations of GFs which favour (i) the
formation of complexes with specic cell receptors in order to
initiate a cascade of reactions, regulating the signal trans-
duction to coordinate cell processes such as tissue formation,
maintenance or regeneration73 and (ii) multivalent complexes
and hampered internalization, thus resulting in special mito-
genic effects.74 However, even though benets have been found
in systems with immobilized GFs over soluble GFs, to achieve
prolonged doses in terms of regenerative properties, there isThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinestill a need for controlling the spatiotemporal presence of GFs at
or near the targeted site to allow e.g. continuous remodeling.
This spatiotemporal control is endogenously found in living
organisms based on interactions found in the microenviron-
ment by elements in the ECM.75 Notwithstanding that some
aspects of these natural concepts to deliver GFs can be recog-
nized in reports as discussed in this feature article, it is evident
that issues such as interaction affinity, GF stability, orientation
and release rates are known to be far from optimal and difficult
to predict in vivo. Some of these aspects have recently been
reported through adopting supramolecular chemistry to
dynamically present peptides and proteins at surfaces.76,77
Further progress in this eld can only take place if chemical and
biological disciplines join forces both to elucidate living bio-
logical systems and to reproduce them from a chemical
synthetic perspective while incorporating the required natural
characteristics for an improved tissue regeneration perfor-
mance when using GFs.78
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